clinical trial · NCT06484686
An Immunity Persistence Study of Booster Dose of Live Attenuated Varicella Vaccine
Sinovac (Dalian) Vaccine Technology Co., Ltd.·phase4·enrolling by invitation·n = 414
VaricellaLive Attenuated Varicella Vaccine
brief summary
This an open-label phase Ⅳ clinical trial of live attenuated varicella vaccine manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.The purpose of this study is to evaluate the immunity persistence of live attenuated varicella vaccine at 6 and 10 years after booster dose.
started
Sep 16, 2024
primary completion
Dec 1, 2028
completion
Dec 1, 2031
last updated
Jan 27, 2025
detailed description
A total of 792 subjects aged 2 to 6 years including in per-protocol set (PPS) of immunogenicity assessment from previous phase Ⅲ clinical trial were enrolled. About 3.0ml of venous blood was collected at 6 and 10 years after booster immunization for antibody detection.
official title
An Open-label Clinical Trial to Evaluate the Immunity Persistence of Live Attenuated Varicella Vaccine At 6 and 10 Years After Booster Dose Immunization with Live Attenuated Varicella Vaccine
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol